In Cellulo pharmacological profiling and genomic editing reveals paralog-specific targets for PA generation during PLC signaling

This study utilizes pharmacological profiling and genomic editing to demonstrate that while DGK inhibitors like R59022 and BMS-502 exhibit paralog-specific effects on DGKalpha, effective reduction of phosphatidic acid levels during PLC signaling requires the simultaneous inhibition of both DGKalpha and phospholipase D enzymes.

The Gist

The Big Picture: The Cell's "Traffic Control" System

Imagine your body's cells are bustling cities. Inside these cities, there are tiny chemical messengers called lipids (fats) that act like traffic signals. One specific signal, called Phosphatidic Acid (PA), is crucial. It tells the cell when to grow, divide, or react to the outside world.

To keep the city running smoothly, the cell needs to produce just the right amount of PA. If there is too little, the city stalls. If there is too much, the city gets chaotic.

The cell has two main construction crews that build PA:

1. The DGK Crew (Diacylglycerol Kinases): There are 10 different versions (paralogs) of these workers.
2. The PLD Crew (Phospholipase D): There are 2 versions of these workers.

The problem? Scientists didn't know exactly which specific worker was doing the heavy lifting during an emergency, and they didn't have good tools to stop the wrong ones without causing a city-wide blackout.

The Problem: The "Broken Tool" (R59022)

For years, scientists used a chemical tool called R59022 to try to stop the DGK crew. They thought it was a precise scalpel that would only stop the specific worker they wanted.

However, the researchers in this paper discovered that R59022 is actually more like a sledgehammer.

• The Surprise: When they used R59022, instead of stopping PA production, it actually increased the PA levels!
• The Toxicity: It was also toxic to the cells, causing them to shrink and die.
• The Confusion: It seems the sledgehammer was hitting so many things at once that it accidentally triggered a panic response in the cell, making it produce more PA instead of less.

The Solution: The "Precision Laser" (BMS-502)

The researchers then tested a newer tool called BMS-502.

• The Result: This tool worked like a precision laser. It stopped the specific DGK workers without hurting the cell or causing a panic.
• The Discovery: They found that BMS-502 actually pulls the DGK workers to the cell's outer wall (the plasma membrane) and then turns them off. It's like a manager walking up to a worker, saying, "Stop working right here," and the worker obeys.

The Investigation: Who is doing the work?

Once they had a reliable tool (BMS-502), they wanted to solve the mystery: Who is actually building the PA signal when the cell gets a message?

They set up a live-action movie inside the cell using special glowing tags (like putting a tiny LED on a worker's helmet).

1. The Trigger: They rang the doorbell (stimulated the cell with a chemical called Carbachol).
2. The Observation:
   • DGKα (The Rookie): This worker was sitting inside the cell but immediately ran to the front door (the membrane) to start building PA.
   • PLD2 (The Veteran): This worker was already standing at the front door, waiting. It didn't need to run; it was just there, ready to work.
   • The Others: The other 8 DGK workers and the other PLD worker stayed inside or did nothing.

The Conclusion: It Takes a Team

The study revealed that to stop the PA signal completely, you can't just stop one crew. You have to stop both:

1. The PLD2 veteran who is always at the door.
2. The DGKα rookie who runs to the door when the alarm sounds.

If you only stop one, the other one keeps building PA, and the signal continues.

Why This Matters (The "In-Cellulo" Revolution)

The most exciting part of this paper isn't just the answer; it's how they found it.

Traditionally, scientists study enzymes by taking them out of the cell and putting them in a test tube (like taking a fish out of the water to study how it swims). This paper introduced a new method they call "In Cellulo Biochemistry."

• The Analogy: Instead of studying the fish in a jar, they studied the fish swimming in the ocean, using high-tech cameras to watch exactly what it does in its natural habitat.
• The Benefit: This allowed them to see that the "sledgehammer" (R59022) behaved differently in the messy, complex ocean of the cell compared to a clean test tube. It also allowed them to find the perfect dose for the "laser" (BMS-502) that works in real life.

Summary

• Old Tool (R59022): A toxic sledgehammer that accidentally made the problem worse.
• New Tool (BMS-502): A safe, precise laser that stops the right workers.
• The Mystery Solved: When a cell gets a signal, it uses a "Veteran" (PLD2) already at the door and a "Rookie" (DGKα) that runs to the door. Both must be stopped to turn off the signal.
• The Legacy: The researchers proved that studying drugs inside the living cell (not just in a test tube) is essential for finding real cures for diseases like high blood pressure or cancer.

Technical Summary

1. Problem Statement

Phosphatidic acid (PA) is a critical signaling lipid generated downstream of Phospholipase C (PLC) activation. In mammals, PA production is mediated by two enzyme families: ten diacylglycerol kinase (DGK) paralogs and two phospholipase D (PLD) paralogs.

• The Challenge: The specific contributions of individual paralogs to PA generation under different signaling contexts remain unclear. This lack of specificity hinders the development of targeted therapies for PLC-related diseases (e.g., hypertension, T-cell proliferation).
• The Tool Limitation: The field has relied heavily on the DGK inhibitor R59022. However, its paralog specificity is debated, and it is often used at high concentrations that may induce off-target effects, cytotoxicity, or paradoxical increases in PA levels, complicating data interpretation. There is a need for a robust platform to characterize inhibitor specificity and efficacy within the native cellular environment.

2. Methodology

The authors employed a novel approach termed "in cellulo biochemistry," combining live-cell imaging, CRISPR/Cas9 genomic editing, and chemically inducible dimerization systems to characterize inhibitors in their native context.

• Cell Lines: HEK293A cells were used as the parental line.
  • Endogenous Tagging: CRISPR/Cas9 was used to knock-in fluorescent tags (NeonGreen or StayGold) at the endogenous loci of six DGK paralogs (α, δ, ε, η, θ, ζ) and two PLD paralogs (PLD1, PLD2).
  • Biosensors:
    • PILS-Nir1: A PA biosensor to quantify PA levels at the plasma membrane (PM) vs. cytosol.
    • C1ab-Prkd1: A DAG biosensor to monitor DAG accumulation.
• Chemically Inducible Dimerization (CID) Assay: To isolate DGK catalytic activity from regulatory translocation events, the authors used a mitochondrial assay.
  • FKBP-BcPI-PLC (produces DAG from PI) and FKBP-DGKα-cat (catalytic fragment of DGKα) were recruited to the mitochondria via Rapamycin-induced dimerization with FRB-Fis1.
  • This allowed the measurement of DGKα catalytic inhibition (PA production) independent of membrane translocation.
• Microscopy:
  • Confocal Microscopy: Used for quantifying biosensor ratios (PM/Cytosol) and large-field imaging.
  • Total Internal Reflection Fluorescence (TIRF): Used to visualize and quantify single-molecule recruitment of endogenous DGK/PLD paralogs to the plasma membrane.
• Lipidomics: Low-microflow targeted lipidomics (LC-MS/MS) was used to quantify specific DAG and PA species.

3. Key Results

A. R59022 is Cytotoxic and Paradoxically Increases PA

• Cytotoxicity: Acute addition of 50 µM R59022 caused significant cell blebbing, rounding, and detachment in HEK293A cells.
• Paradoxical PA Increase: Contrary to the expectation that a DGK inhibitor should lower PA, R59022 treatment led to a significant increase in PA levels (visualized by PILS-Nir1 translocation to the PM).
• Mechanism: Lipidomics revealed that R59022 elevated unsaturated DAGs and saturated PAs. The authors hypothesize that R59022 acts as a broad-spectrum DGK inhibitor that also activates PKC or PLD, or that its lipophilic nature disrupts membrane integrity, leading to off-target PA generation.
• Recruitment: R59022 recruited endogenous DGKα, DGKθ, and DGKζ to the PM, but this recruitment did not overcome its inhibitory effect in the mitochondrial assay (where the catalytic domain was tethered).

B. BMS-502 is a Potent, Non-Toxic, Paralog-Specific Inhibitor

• Efficacy: Unlike R59022, BMS-502 (at 1 µM) did not cause cytotoxicity or increase PA levels. Instead, it effectively inhibited DGK activity.
• Potency: In the mitochondrial assay, BMS-502 inhibited DGKα catalytic activity with an IC50 of ~100 nM.
• Recruitment vs. Inhibition: BMS-502 also recruited endogenous DGKα, DGKθ, and DGKζ to the PM. Crucially, the EC50 for recruitment overlapped significantly with the IC50 for inhibition (both ~100 nM). This supports a model where BMS-502 increases the affinity of DGKs for membrane lipids (recruitment) as part of its inhibitory mechanism, rather than acting as a simple competitive inhibitor that can be outcompeted by substrate.
• Specificity: BMS-502 was confirmed to inhibit DGKα, DGKθ, and DGKζ in HEK293A cells.

C. Dissecting PA Generation During PLC Activation

Using BMS-502 and the PLD inhibitor FIPI, the authors deconvolved the sources of PA during muscarinic receptor (M3) stimulation with Carbachol (CCh):

• DGKα Recruitment: CCh stimulation transiently recruited endogenous DGKα to the PM (peaking at ~135 seconds).
• PLD2 Localization: PLD2 was constitutively localized to the PM, while PLD1 remained cytosolic.
• Synergistic Requirement:
  • Inhibiting DGKs alone (BMS-502) only slightly reduced PA levels.
  • Inhibiting PLDs alone (FIPI) slowed the initial rate of PA production but levels eventually recovered.
  • Dual Inhibition: Simultaneous inhibition of DGKs (BMS-502) and PLDs (FIPI) almost completely abolished PA production.
• Conclusion: PA generation during PLC signaling is a two-phase process: PLD2 drives the initial rapid burst of PA, while DGKα (recruited by signaling) sustains PA production in later stages.

4. Key Contributions

1. Validation of "In Cellulo Biochemistry": The study establishes a new platform for characterizing drug targets in live cells. By measuring recruitment (EC50) and catalytic inhibition (IC50) in the same cellular environment, it provides a more physiologically relevant profile than traditional in vitro assays.
2. Re-evaluation of R59022: The paper demonstrates that R59022 is unsuitable for studying DGK inhibition in live HEK293A cells due to cytotoxicity and paradoxical PA elevation, cautioning against its use in future studies without rigorous dose optimization.
3. Characterization of BMS-502: Confirms BMS-502 as a potent, non-toxic inhibitor of DGKα, DGKθ, and DGKζ, with a mechanism involving membrane recruitment.
4. Paralog-Specific Model of PA Signaling: Defines a specific temporal and paralog-specific model for PLC signaling: PLD2 provides basal and early PA, while DGKα is recruited to provide sustained PA.

5. Significance

• Therapeutic Implications: The findings identify DGKα and PLD2 as critical, druggable targets for modulating PLC signaling pathways involved in diseases like hypertension and T-cell malignancies.
• Methodological Advancement: The "in cellulo biochemistry" approach bridges the gap between biochemical assays and cellular physiology, offering a powerful tool for lipid enzymology and drug discovery. It allows researchers to determine if a drug's cellular efficacy is limited by permeability, off-target effects, or complex regulatory mechanisms (like translocation) that are missed in lysate-based assays.
• Clarification of Signaling Dynamics: The study resolves the ambiguity regarding the relative contributions of DGKs and PLDs, showing that both are essential and operate in a coordinated, time-dependent manner to maintain membrane homeostasis.